{
    "clinical_study": {
        "@rank": "73911", 
        "acronym": "VISMOLY", 
        "arm_group": {
            "arm_group_label": "Vismodegib", 
            "arm_group_type": "Experimental", 
            "description": "Vismodegib 150 mg will be administrated orally at a dosage of 150 mg (1 capsule) once a day during 12 months."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the efficacy of Vismodegib drug in treatment of\n      patients with relapsed or refractory B-cell lymphoma or chronic lymphocytic leukemia (CLL)."
        }, 
        "brief_title": "Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diffuse Large B-cell Lymphoma", 
            "\"Indolent\" Non-hodgkin Lymphoma", 
            "Primary Central Nervous System Lymphoma", 
            "Chronic Lymphocytic Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a multicenter open-label phase II study.\n\n      Primary objective:\n\n      To evaluate the efficacy of vismodegib in patients with relapsed/refractory B-cell lymphoma\n      and CLL as measured by the best overall response rate (ORR) during the treatment period.\n\n      Secondary objectives:\n\n        -  To evaluate the tolerability and the safety of vismodegib in patients with\n           relapsed/refractory B-cell lymphoma and CLL\n\n        -  To evaluate the efficacy of vismodegib in patients with relapsed/refractory B-cell\n           lymphoma and CLL by measuring the overall (OR) and complete response (CR) rate during\n           the study period, the maximum tumor shrinkage, the duration of response, the\n           progression-free survival (PFS) and the overall survival (OS).\n\n        -  To examine the expression of GLI-1 and other Hedgehog (Hh) signalling components in the\n           tumor specimens before and during treatment with vismodegib and corresponding efficacy\n           in patients.\n\n           44 patients will be included in the study equally distributed into 4 cohorts according\n           to their histological subtype:\n\n        -  Cohort 1: 11 patients with Diffuse large B-cell lymphomas (DLBCL)\n\n        -  Cohort 2: 11 patients with \"indolent\" lymphomas (iNHL): Follicular (FL), mantle cell\n           (MCL) and marginal zone lymphoma (MZL) lymphoplasmacytic lymphoma (LPL)/ Waldenstrom\n           macroglobulinemia (WM), small lymphocytic lymphoma (SLL)\n\n        -  Cohort 3: 11 patients with Primary central nervous system lymphomas (PCNSL)\n\n        -  Cohort 4: 11 patients with Chronic lymphocytic leukemia (CLL).\n\n      After 28 days screening period (Baseline), each patient will be treated by Vismodegib 150 mg\n      per os during for a maximum of 12 months until disease progression, unacceptable toxicities,\n      patient consent withdrawal, death, reasons deemed by the treating physician or study\n      termination by the Sponsor.\n\n      Tumour assessment (clinical examination, laboratory tests, abdominal and chest CT scan (for\n      PCNSL only at baseline), +/- PET scan for DLBCL, +/- brain MRI and CSF examination and\n      ophthalmic examination for PCNSL, +/- bone marrow examination (except for PCNSL) will be\n      performed at baseline, and then every 2 months during the first 6 months of treatment, and\n      every 3 months thereafter until disease progression or up to 6 months after study treatment\n      stop.\n\n      Response to treatment will be assessed also by Pharmacodynamic study in tumor samples by\n      immunohistochimic and qPCR analysis at baseline and after one month of treatment with\n      vismodegib.\n\n      Pharmacokinetic studies (before and after 1 month of treatment) will also be performed.\n\n      After study treatment discontinuation, the patients will be followed up every 3 months until\n      disease progression or up to 6 months (after 1 year treatement)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed diagnosis of B-cell lymphoma (DLBCL, MCL, FL, MZL, LPL/WM,\n             SLL or PCNSL) or CLL (Matutes score \u22654) requiring treatment that is recurrent after\n             at least one prior therapy for which no potentially curative therapy nor better\n             treatment option is available. Specifically, the patient should have received all\n             treatments considered to be standards of care, including stem cell transplantation\n             (when appropriate, if patient eligible), and agents known to have significant\n             clinical efficacy in their disease.Patient must be eligible for tumor biopsy. Biopsy\n             at relapse is mandatory for all patients except for PCNSL (optional) and should\n             provide enough tumor tissue for biological tests (paraffin-embedded and frozen or\n             RNAlater-conserved tissue).\n\n          -  Age 18 and older\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2\n\n          -  Signed inform consent\n\n          -  Life expectancy \u2265 3 months\n\n          -  Patients who have received up to a maximum of 4 lines of treatment (including\n             radiotherapy)\n\n          -  Patients must have recovered from all toxicities related to prior treatments to \u2264\n             grade 1.\n\n          -  Adequate Laboratory Parameters (unless abnormalities are related to underlying\n             disease) within 28 days prior to signing informed consent, including:\n\n               -  Absolute neutrophil count (ANC) \u2265 1000/\u03bcL\n\n               -  Platelet \u2265 75,000/\u03bcL\n\n               -  Hemoglobin > 8.5 g/dL\n\n               -  Total bilirubin \u2264 1.5 x upper limit of normal (UNL)\n\n               -  Hepatic enzymes (AST, ALT) \u2264 3 x institutional ULN\n\n          -  Measurable disease:\n\n               -  Cohort 1 and 2 (DLBCL and iNHL): Bi-dimensionally measurable disease at CT scan\n                  with at least 2cm in their longest diameter.\n\n               -  Cohort 3 (PCNSL): Measurable PCNSL on MRI with gadolinium enhancement (no\n                  minimal size) or, for intraocular lymphoma (IOL), measurable disease at\n                  fundoscopic examination with elevated level of IL10 (>10 pg/ml) in the acqueous\n                  humor.\n\n               -  Cohort 4 (CLL): Measurable disease assessable in the blood (lymphocytosis,\n                  cytopenia) and/or by imaging (bi-dimensionally measurable disease at CT scan\n                  with at least 2cm in their longest diameter)\n\n          -  Patient must be able to take oral medication\n\n          -  Females of childbearing potential (FCBP) must :\n\n               -  have a negative pregnancy test (serum or urine,  sensitivity < or = 25IU HCG/L)\n                  within 96 hours prior to starting study drug administration.\n\n               -  Agree to use two reliable forms of contraception or to practice complete\n                  abstinence from heterosexual contact during whole treatment period and up to 7\n                  months after discontinuation of study drug treatment\n\n          -  Male patients must agree :\n\n               -  to use a condom  with female of childbearing potential or to practice complete\n                  abstinence during whole treatment period and up to 7 months after\n                  discontinuation of study drug  treatment.\n\n               -  To abstain from donating semen during whole treatment period and up to 7 months\n                  after discontinuation of study drug  treatment\n\n          -  For all patients receiving vismodegib (GDC-0449):\n\n               -  To agree to abstain from donating blood during the whole study and for at least\n                  7 months after discontinuation of study drug  treatment\n\n               -  To agree not to share the study medication with another person\n\n        Exclusion Criteria:\n\n          -  Pregnant or breastfeeding lactating females.\n\n          -  For CLL patients, clinically significant auto-immune cytopenia, Coombs-positive\n             hemolytic anemia as judged by the treating physician\n\n          -  Concomitant anti-tumor therapy (e.g., chemotherapy, corticosteroids, other targeted\n             therapy, radiation therapy). Corticosteroids may be authorized for PCNSL only during\n             maximum 3 weeks (before and/or at the beginning of treatment with vismodegib) at a\n             maximum dose of 1mg/kg of prednisone or equivalent.\n\n          -  Use of any standard or experimental anti-cancer drug therapy within 28 days prior to\n             the study drug therapy (Day 1).\n\n          -  Patients with severe renal failure (creatinine clearance < 30 ml/min according to\n             Cockcroft & Gault formula) and/or undergoing dialysis.\n\n        Note: Patients with moderate renal insufficiency (i.e. creatinine clearance \u2265 30 ml/min)\n        may be included.\n\n          -  Uncontrolled and/or unstable concomitant disease such as infection requiring\n             treatment with intravenous antibiotics.\n\n          -  HIV positive serology\n\n          -  Active hepatitis B or C\n\n          -  History of other disease, metabolic dysfunction, physical examination, or clinical\n             laboratory finding giving reasonable suspicion of a disease or condition that\n             contraindicates use of an investigational drug or that might affect interpretation of\n             the study results or to expose the patient to high risk from treatment complications.\n\n          -  Patients unable to comply with the protocol requirements according to the\n             investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01944943", 
            "org_study_id": "VISMOLY"
        }, 
        "intervention": {
            "arm_group_label": "Vismodegib", 
            "description": "150 mg (1 capsule) of Vismodegib per day orally in continue during 12 months", 
            "intervention_name": "Vismodegib", 
            "intervention_type": "Drug", 
            "other_name": "GDC-0449, ERIVEDGE\u00ae"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "refractory/relapsed", 
            "diffuse large B-cell lymphoma", 
            "\"indolent\" non-hodgkin lymphoma", 
            "Primary central nervous system lymphoma", 
            "chronic lymphocytic leukemia"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "contact": {
                    "email": "corinne.haioun@hmn.aphp.fr", 
                    "last_name": "Corinne HAIOUN, Professor", 
                    "phone": "+ 33 1 49 81 41 54"
                }, 
                "facility": {
                    "address": {
                        "city": "Creteil", 
                        "country": "France", 
                        "zip": "94010"
                    }, 
                    "name": "H\u00f4pital Henri MONDOR"
                }, 
                "investigator": [
                    {
                        "last_name": "Corinne HAIOUN, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Karim BELHADJ, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Catalina ENACHE, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jehan DUPUIS, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Isabelle GAILLARD, Doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "olivier.casasnovas@chu-dijon.fr", 
                    "last_name": "Ren\u00e9-Olivier CASASNOVAS", 
                    "phone": "+ 33 3 80 29 50 41"
                }, 
                "facility": {
                    "address": {
                        "city": "Dijon", 
                        "country": "France", 
                        "zip": "21000"
                    }, 
                    "name": "CHU Dijon _ H\u00f4pital d'Enfants"
                }, 
                "investigator": [
                    {
                        "last_name": "Ren\u00e9-Olivier CASASNOVAS, Doctor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Jean-No\u00ebl BASTIE, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Denis CAILLOT, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Emmanuelle FERRANT, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Ingrid LAFON, Doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "franck.morschhauser@chru-lille.fr", 
                    "last_name": "Franck MORSCHHAUSER, Doctor", 
                    "phone": "+ 33 3 20 44 60 68"
                }, 
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59800"
                    }, 
                    "name": "CHRU de Lille _ H\u00f4pital Huriez"
                }, 
                "investigator": [
                    {
                        "last_name": "Franck MORSCHHAUSER, Doctor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Louis TERRIOU, Doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "steven.legouill@chu-nantes.fr", 
                    "last_name": "Steven LE GOUILL, Professor", 
                    "phone": "+33 2 40 08 32 71"
                }, 
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France", 
                        "zip": "44093"
                    }, 
                    "name": "CHU de Nantes _ H\u00f4tel Dieu"
                }, 
                "investigator": [
                    {
                        "last_name": "Steven LE GOUILL, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Nicolas BLIN, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Viviane DUBRUILLE, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Beatrice MAHE, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Cyrille TOUZEAU, Doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "catherine.thieblemont@sls.aphp.fr", 
                    "last_name": "Catherine THIEBLEMONT, Professor", 
                    "phone": "+ 33 1 42 49 92 36"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75475"
                    }, 
                    "name": "H\u00f4pital Saint-Louis"
                }, 
                "investigator": [
                    {
                        "last_name": "Catherine THIEBLEMONT, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Pauline BRICE, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Patricia FRANCHI, Doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "krimo.bouabdallah@chu-bordeaux.fr", 
                    "last_name": "Krimo Kamal BOUABDALLAH, Doctor", 
                    "phone": "+ 33 5 57 65 65 11"
                }, 
                "facility": {
                    "address": {
                        "city": "Pessac", 
                        "country": "France", 
                        "zip": "33604"
                    }, 
                    "name": "CHU Haut L\u00e9v\u00e8que"
                }, 
                "investigator": [
                    {
                        "last_name": "Krimo Kamal BOUABDALLAH, Doctor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Marie-Sarah DILHUYDY, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "C\u00e9dric DUCLOS, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Axelle LASCAUX, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "No\u00ebl MILPIED, Professor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gilles.salles@chu-lyon.fr", 
                    "last_name": "Gilles SALLES, Professor", 
                    "phone": "+ 33 4 78 86 43 01"
                }, 
                "facility": {
                    "address": {
                        "city": "Pierre-B\u00e9nite", 
                        "country": "France", 
                        "zip": "69495"
                    }, 
                    "name": "CH Lyon Sud"
                }, 
                "investigator": [
                    {
                        "last_name": "Gilles SALLES, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Fadh\u00e8la BOUAFIA-SAUVY, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Bertrand COIFFIER, Professor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Daniel ESPINOUSE, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Lionel KARLIN, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Laure LEBRAS, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Anne-Sophie MICHALLET, Doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "roch.houot@chu-rennes.fr", 
                    "last_name": "Roch HOUOT, Doctor", 
                    "phone": "+ 33 2 99 28 98 73"
                }, 
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France", 
                        "zip": "35003"
                    }, 
                    "name": "CHU Pontchaillou"
                }, 
                "investigator": [
                    {
                        "last_name": "Roch HOUOT, Doctor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Marc BERNARD, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Charles DAURIAC, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Sophie DE GUIBERT, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Anne-Violaine DONCKER, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Martine ESCOFFRE, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Thierry LAMY DE LA CHAPELLE, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Stanislas NIMUBONA, Doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "herve.tilly@chb.unicancer.fr", 
                    "last_name": "Herv\u00e9 TILLY, Professor", 
                    "phone": "+ 33 2 32 08 22 02"
                }, 
                "facility": {
                    "address": {
                        "city": "Rouen", 
                        "country": "France", 
                        "zip": "76038"
                    }, 
                    "name": "Centre Henri Becquerel"
                }, 
                "investigator": [
                    {
                        "last_name": "Herv\u00e9 TILLY, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Oana BREHAR, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Nathalie CARDINAEL, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Nathalie CONTENTIN, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Marie-laure FONTOURA, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Carole FRONVILLE, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Fabrice JARDIN, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "H\u00e9l\u00e8ne LANIC, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Emilie LEMASLE, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Pascal LENAIN, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "St\u00e9phane LEPRETRE, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Aspasia STAMATOULLAS, Doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "carole.soussain@curie.net", 
                    "last_name": "Carole SOUSSAIN, Doctor", 
                    "phone": "+ 33 1 47 11 15 36"
                }, 
                "facility": {
                    "address": {
                        "city": "Saint-Cloud", 
                        "country": "France", 
                        "zip": "92210"
                    }, 
                    "name": "H\u00f4pital Ren\u00e9 Huguenin _ Institut Curie"
                }, 
                "investigator": [
                    {
                        "last_name": "Carole SOUSSAIN, Doctor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Alain BOURGUIGNAT, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Sylvie GLAISNER, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Maud JANVIER, Doctor", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jacques VARGAFTIG, Doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia", 
        "overall_contact": {
            "email": "anastassia.traore@lysarc.org", 
            "last_name": "Anastassia TRAORE", 
            "phone": "+33 (0)4 72 24 41 74"
        }, 
        "overall_official": {
            "last_name": "Roch HOUOT, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "ORR will be measured by the best overall response (complete response (CR), uncofirmed complete response (CRu) or partial response (PR)) recorded during whole treatment period from the baseline until the end of treatment.\nORR will be assessed according to Cheson 1999 for DLBCL and iNHL, according to Abey 2005 (IPCG response criteria) for PCNSL and to Hallek 2008 (IWCLL response criteria) for CLL.", 
            "measure": "The best overall response rate(ORR)", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01944943"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall response rate will be evaluated as ORR, CR, CRu, PR, stable disease (SD) and progressive disease (PD) after 2, 4, 6, 9, and 12 months of treatment and every 3 months for 6 months after treatment discontinuation, until disease progression.", 
                "measure": "Overall Response rate", 
                "safety_issue": "No", 
                "time_frame": "2, 4, 6, 9, and 12 months"
            }, 
            {
                "description": "Progression-Free Survival will be measured from the date of inclusion to the date of first documented disease progression, relapse or death from any cause. Responding patients and patients who are lost to follow up will be censored at their last tumor assessment date.", 
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 year"
            }, 
            {
                "description": "Duration of response will be measured from the time of attainment of first CR, CRu or PR to the date of first documented disease progression, relapse or death from any cause. Subjects with no documented progression after CR, CRu or PR will be censored at the last tumor assessment date.", 
                "measure": "Response Duration", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 year"
            }, 
            {
                "description": "Overall survival will be measured from the date of inclusion to the date of death from any cause. Alive patients will be censored at their last date known to be alive.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 year"
            }, 
            {
                "description": "Hh signaling cascade will be evaluated in tumors at baseline and at the end of cycle 1 (at Day 28 +/- 7 days) in order to:\nStudy pharmacodynamic of the drug (extinction of Hh signaling under treatment with Vismodegib)\nSearch for correlation between Hh signaling and clinical response to Vismodegib", 
                "measure": "Correlation between Hedgehog (Hh) signaling in the tumor and the efficacy of Vismodegib", 
                "safety_issue": "No", 
                "time_frame": "At baseline and at 28 days (+/- 7 days)"
            }, 
            {
                "description": "Description of all adverse events (AEs), laboratory data, vital signs and ECOG performance status, performed by cycle/visit and for the entire study.", 
                "measure": "Safety endpoints", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 year"
            }, 
            {
                "description": "Overall response will also be assessed using the Cheson 2007 criteria in patients with DLBCL. Patient without response assessment (due to whatever reason) will be considered as non-responder.", 
                "measure": "Overall Response rate", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "The Lymphoma Academic Research Organisation", 
        "sponsors": {
            "collaborator": {
                "agency": "Roche Pharma AG", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "The Lymphoma Academic Research Organisation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}